IP Library Granted Patent US 7,220,433
Granted Patent B2
US 7,220,433 · App. 10/608,507 · Granted May 22, 2007

Compositions for parenteral administration and sustained-release of therapeutic agents

Assignee: Ethicon, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,220,433
App. No.
10/608,507
Granted
May 22, 2007
Kind
B2
Abstract

The present invention is directed to parenterally-administrable microparticles for providing sustained-release of a therapeutic agent in the body, where the microparticles include a polymeric core containing a therapeutically effective amount of a therapeutic agent disposed therein, a first film encapsulating the core, the first film prepared from a first biodegradable polymer soluble in an appropriate solvent therefore, and a second film encapsulating the core and the first film, the second film prepared from a biodegradable polymer soluble in an appropriate solvent therefore, wherein the first film is insoluble in the solvent used to prepare the second film, and to parenterally-administrable compositions containing such microparticles dispersed in a suitable carrier therefore.

Claims (24)

1. A parenterally-administrable microparticle for providing sustained-release of a therapeutic agent in the body, comprising:

a core comprising a therapeutically effective amount of a therapeutic agent,

a first film comprising a first biodegradable polymer comprising hydroxypropyl-methyl cellulose encapsulating said core, and

a second film applied to said first film and encapsulating said first film and said core, said second film comprising a second biodegradable polymer comprising an alkyd polyester wax soluble in an appropriate solvent for said second polymer, wherein said core comprises a third biodegradable polymer comprising an alkyd polyester wax having said therapeutic agent dispersed there through, and said first film is insoluble in and impervious to said solvent for said second biodegradable polymer.

2. The microparticle of claim 1 wherein said third biodegradable polymer and said second biodegradable polymer are the same.

3. The microparticle of claim 1 wherein said third biodegradable polymer and said second polymer are different.

4. The microparticle of claim 2 wherein said second and third biodegradable polymers comprise poly(monostearoyl glycerol-co-succinate) and said first biodegradable polymer comprises hydroxypropyl-methyl cellulose.

5. The microparticle of claim 1 comprises from about 0.1 to about 50 percent by weight of said therapeutic agent.

6. The microparticle of claim 5 wherein said therapeutic agent is selected from the group consisting of proteins, peptides, growth factors, and drugs.

7. The microparticle of claim 1 comprising from about 0.1 to about 50% of said first film by weight of said core.

8. The microparticle of claim 1 comprising from about 0.5 to about 200% of said second film by weight of said core.

9. Compositions for patenteral administration and sustained-release of therapeutic agents' comprising:

a microparticle, said microparticle comprising,

a core comprising a therapeutically effective amount of a therapeutic agent,

a first film comprising a first biodegradable polymer comprising hydroxypropyl-methyl cellulose encapsulating said core, and

a second film applied to said first film and encapsulating said first film and said core, said second film comprising a second biodegradable polymer comprising an alkyd polyester wax soluble in an appropriate solvent for said second polymer, wherein said core comprises a third biodegradable polymer comprising an alkyd polyester wax having said therapeutic agent dispersed there through and said first film is insoluble in and impervious to said solvent for said second biodegradable polymer, and;

a biocompatible suitable carrier for said microparticle.

10. The composition of claim 9 wherein said third biodegradable polymer and said second biodegradable polymer are the same.

11. The composition of claim 9 wherein said third biodegradable polymer and said second polymer are different.

12. The composition of claim 10 wherein said second and third biodegradable polymers comprise poly(monostearoyl glycerol-co-succinate) and said first biodegradable polymer comprises hydroxypropyl-methyl cellulose.

13. The composition of claim 9 comprising from about 0.1 to about 50 percent by weight of said therapeutic agent.

14. The composition of claim 13 wherein said therapeutic agent is selected from the group consisting of proteins, peptides, growth factors, and drugs.

15. The microparticle of claim 9 comprising from about 0.1 to about 50% of said first film by weight of said core.

16. The microparticle of claim 9 comprising from about 0.5 to about 200% of said second film by weight of said core.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2013
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ENDO-SURGERY, INC.
Reel/Frame 029595/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ETHICON ENDO-SURGERY, INC.
Reel/Frame 029496/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INC.
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026286/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2004
From: CUI, HAN; ROSENBLATT, JOEL; KATARIA, RAM L.; WU, CHUANBIN
To: ETHICON, INC.
Reel/Frame 014961/0945 →
Continuity (1)
Related Publication 20040265383A1 · Dec 30, 2004